Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome.
about
Advances in salivary gland gene therapy - oral and systemic implicationsVasoactive intestinal peptide inhibits TNF-alpha-induced apoptotic events in acinar cells from nonobese diabetic mice submandibular glands.The expression of vasoactive intestinal peptide receptor 1 is negatively modulated by microRNA 525-5p.Interleukin-12 induces salivary gland dysfunction in transgenic mice, providing a new model of Sjögren's syndrome.Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.Local expression of tumor necrosis factor-receptor 1:immunoglobulin G can induce salivary gland dysfunction in a murine model of Sjögren's syndrome.IL17: potential therapeutic target in Sjögren's syndrome using adenovirus-mediated gene transfer.Cytokines in Sjogren's syndrome: potential therapeutic targets.Pathogenic effect of interleukin-17A in induction of Sjögren's syndrome-like disease using adenovirus-mediated gene transferTransgenic α-1-antitrypsin secreted into the bloodstream from salivary glands is biologically activeGene delivery in salivary glands: from the bench to the clinicSingle nucleotide polymorphisms in the 3'UTR of VPAC-1 cooperate in modulating gene expression and impact differently on the interaction with miR525-5p.Horizons in Sjögren's syndrome genetics.Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: implications for exocrine pathogenesis and treatment.Vasoactive Intestinal Peptide in Early Spondyloarthritis: Low Serum Levels as a Potential Biomarker for Disease SeverityIL-17 sequestration via salivary gland gene therapy in a mouse model of Sjogren's syndrome suppresses disease-associated expression of the putative autoantigen Klk1b22Sjögren syndrome: what and where are we looking for?The management of Sjögren's syndrome.Tuning inflammation with anti-inflammatory neuropeptides.Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disordersDecoding the chemokine network that links leukocytes with decidual cells and the trophoblast during early implantation.Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy.Gene therapy: some history, applications, problems, and prospects.Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders.Gene therapy of the rheumatic diseases: 1998 to 2008.Transient TWEAK overexpression leads to a general salivary epithelial cell proliferation.Neuropeptides as pleiotropic modulators of the immune response.Tolerance induction at the early maternal-placental interface through selective cell recruitment and targeting by immune polypeptides.Classification criteria and treatment modalities in primary Sjögren's syndrome.Anti-Inflammatory Effects of Modified Adenoviral Vectors for Gene Therapy: A View through Animal Models Tested.Introduction of hIGF-1 gene into bone marrow stromal cells and its effects on the cell's biological behaviors.Neutralizing antibodies against adeno-associated viruses in Sjögren's patients: implications for gene therapy.Adult stem cells and tissue engineering strategies for salivary gland regeneration: a reviewEffect of VIP on the balance between cytokines and master regulators of activated helper T cells.NOD mouse model for Sjögren's syndrome: lack of longitudinal stability.Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis.Protective effect of Zengye Decoction () on the submandibular glands in nonobese diabetic mice.Transdifferentiation of bone marrow-derived mesenchymal stem cells into salivary gland-like cells using a novel culture method.Chronic inflammation enhances NGF-β/TrkA system expression via EGFR/MEK/ERK pathway activation in Sjögren's syndrome.RNA sensors in human osteoarthritis and rheumatoid arthritis synovial fibroblasts: immune regulation by vasoactive intestinal peptide.
P2860
Q28084318-D996EBE7-1BA6-4D44-AE14-1637D97D53E5Q33428324-684B8934-4348-40E2-9235-5309609B4FF7Q33656489-C03258E2-4B01-4002-AEE6-04F43CE90538Q33767896-C0EED45B-316A-4E43-85A5-899A7DD3BEDBQ34238010-9CB76663-542B-4775-A777-31006045574FQ34413324-0E14BFCA-E228-450A-9161-8806912C1A5CQ34448523-54748D19-EB74-4EA6-B111-88D2F111E50CQ34601660-98A8442A-21B0-4A0E-BEA7-E4C49E5BE97AQ34614045-9D7D6432-A017-4B5B-B53B-70B9EEB582BEQ35019400-8C97F402-E502-46B2-B6DE-05AFDA790878Q35255990-9A55C9F9-D6B1-48B6-A651-4DD36F614EEAQ35414146-5FA99EC6-32B0-4472-B705-7FDFE702BDC4Q35570872-BCE07790-D5B4-414A-B179-A394A5B8CF8CQ35638200-714F9734-043A-4B60-8D6C-11C63E8B21ADQ35768646-95060DF6-2D78-4916-B087-48516A23A5B0Q35923212-02BF8BCA-4478-4B56-8762-F57091CD8BDDQ36243207-B38085FC-6712-4198-970C-E81F908339CBQ36577478-314E7A3E-263C-4361-B5BB-399F993C0520Q36764912-AD6E01D6-862F-47A8-9A50-20198045B331Q36830470-053EF67B-DE7D-4E54-A832-CCEECA7E5AADQ36857976-633E33B2-CA2B-4458-AD47-F89079022B1AQ36969911-94C2C3B6-4323-4EA7-87E1-0CE16460B40AQ37109090-F7FFA067-849A-4D0C-BECA-8FEFB8ACA91FQ37191369-4618865B-871A-48B6-B888-1DEC67EAE86BQ37207021-D876BF86-ED27-4FDE-AF00-64F59E424345Q37383983-740FA9B7-8148-4B1C-B0CD-831C0FDD8C0CQ37898396-1C80DC3D-CC61-42CC-92FE-81468BE31E6AQ38081181-59CE4FFB-669F-4FBC-A384-7B4281D06AA9Q38197287-43EBEFD5-C689-42B9-B824-0583F01D01FCQ38849248-D079A15E-5544-445D-8CF1-7A41CAD941C4Q40006848-6808BBF0-D8F0-4839-9C70-87F008A843D6Q40354609-8CFB928D-8A12-41B8-A3F1-D6A29143E811Q42176563-A36DC071-52B7-465C-9FA7-E686D04C7110Q43554142-DF09C4D5-0432-4FFA-B14E-E7FE0F1F5634Q45863257-EF2A5E61-5C8B-4A21-93D1-9B1D6671CE20Q48120810-805F6221-2463-47F8-A987-9963DAD9E87DQ48826121-9AAF46C2-E479-443E-A371-EA051D4C4D9BQ53583071-F74EF70C-D753-4502-8121-BF9D77A8EF1DQ54375857-D16BA636-C8E7-41A0-B218-F7B0FD634404Q54386794-8CF38B86-F5C4-42CC-9A3C-CAD5D099AB72
P2860
Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Effect of human vasoactive int ...... e model of Sjogren's syndrome.
@ast
Effect of human vasoactive int ...... e model of Sjogren's syndrome.
@en
type
label
Effect of human vasoactive int ...... e model of Sjogren's syndrome.
@ast
Effect of human vasoactive int ...... e model of Sjogren's syndrome.
@en
prefLabel
Effect of human vasoactive int ...... e model of Sjogren's syndrome.
@ast
Effect of human vasoactive int ...... e model of Sjogren's syndrome.
@en
P2093
P2860
P356
P1476
Effect of human vasoactive int ...... e model of Sjogren's syndrome.
@en
P2093
A P Cotrim
F Mineshiba
P2860
P304
P356
10.1136/ARD.2005.038232
P407
P577
2005-06-23T00:00:00Z